- Home
- DAVI vs ABEO Comparison
DAVI vs ABEO Comparison
Compare DAVI & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$0.91
N/A
Current Price
$2.41
Company Overview
Basic Information| Metric | DAVI | ABEO |
|---|---|---|
| Founded | 2022 | 1974 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.3M | 282.5M |
| IPO Year | 2025 | 2005 |
Fundamental Metrics
Financial Performance| Metric | DAVI | ABEO |
|---|---|---|
| Price | $0.91 | $2.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $15.56 |
| AVG Volume (30 Days) | 435.8K | ★ 1.9M |
| Earning Date | 04-06-2027 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $693.00 |
| Revenue Next Year | N/A | $138.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $1.20 | $2.22 |
| 52 Week High | $6.05 | $7.65 |
Technical Indicators
Market Signals| Indicator | DAVI | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 12.25 | 21.11 |
| Support Level | N/A | N/A |
| Resistance Level | $1.80 | $5.77 |
| Average True Range (ATR) | 0.41 | 0.32 |
| MACD | -0.09 | -0.18 |
| Stochastic Oscillator | 0.03 | 12.69 |
Price Performance
Historical Comparison DAVI
ABEO
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.